비교리스트

 카트 문의
시장보고서
상품코드
1344307

나노테크놀러지 약물전달 시장 : 제제별, 용도별 - 세계 기회 분석 및 산업 예측(2023-2032년)

Nanotechnology Drug Delivery Market By Formulation, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 245 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

나노테크놀러지 약물전달 시장은 2022년 875억 달러로 평가되며, 2023년부터 2032년까지 CAGR 9.1%로 성장하여 2032년에는 2,095억 달러에 달할 것으로 추정됩니다.

나노테크놀러지는 표적 치료, 약효 강화, 환자 결과 개선 등의 과제를 극복할 수 있는 혁신적인 솔루션을 제공함으로써 약물전달 분야에 혁명을 일으켰습니다. 나노테크놀러지 약물전달 시장은 괄목할 만한 성장세를 보이고 있으며, 의료의 미래에 엄청난 잠재력을 가지고 있습니다. 나노입자, 나노 에멀젼 및 나노 캐리어는 약물전달 시스템에 사용되는 나노 기술의 주요 구성요소 중 일부입니다. 이러한 나노 스케일 구조는 높은 표면적 대 부피 비율과 치료제를 캡슐화하여 신체의 특정 표적 부위에 전달할 수 있는 능력과 같은 독특한 물리 화학적 특성을 가지고 있습니다.

Nanotechnology Drug Delivery Market-IMG1

나노테크놀러지 약물전달 시장을 주도하는 것은 만성 질환의 유병률 증가와 나노기술의 발전입니다. 만성 질환의 증가는 나노테크놀러지 약물전달 시장의 주요 촉진요인으로 부상하고 있습니다. 암, 당뇨병, 심혈관 질환, 호흡기 질환과 같은 만성 질환은 전 세계적으로 심각한 건강 문제를 야기하고 있습니다. 국제당뇨병연맹에 따르면, 2021년에는 약 5억 3,700만 명이 당뇨병을 앓고 있는 것으로 추정됩니다. 또한 이 자료에 따르면, 2030년까지 당뇨병 환자 수는 6억 4,300만 명, 2045년까지 7억 8,300만 명으로 늘어날 것으로 예측됩니다. 예를 들어, 모나쉬 대학, RMIT 대학, 멜버른 대학, 베이커 연구소의 연구원들은 현재 인슐린에 없는 포도당에 반응하는 시스템을 개발했습니다.

임상 전 연구 결과, 인슐린이 꼭 필요할 때만 인슐린을 분비하는 우수한 인공 췌장 시스템이 설계되어 혈당 수치를 보다 안정적으로 조절할 수 있습니다. 이 혁신적인 나노당질 플랫폼은 포도당 수치에 반응하는 신속하고 일관된 인슐린 분비를 촉진하여 지속시간과 지능 면에서 다른 시스템을 능가했습니다. 약물전달의 정확성, 표적화 및 개인 맞춤형 의료를 향상시키는 나노기술의 고유한 능력은 만성질환 관리와 관련된 문제를 해결할 수 있는 유망한 솔루션으로 자리매김하고 있습니다. 이처럼 만성 질환의 유병률 증가는 나노테크놀러지 약물전달 시장의 성장을 이끄는 주요 원동력이 되고 있습니다.

또한, 나노 의약품의 기술 발전은 나노테크놀러지 약물전달 시장의 성장에 중요한 역할을 할 것으로 예상됩니다. 전통적인 약물전달 시스템(DDS)의 한계로 인해 나노 캐리어의 인기가 크게 증가하고 있습니다. 예를 들어, 애리조나 주립대 과학자들은 다양한 형태로 변형할 수 있는 능력으로 인해 '종이접기 나노 로봇'을 만들었습니다. 이것은 혈액 응고 효소로 코팅된 평평한 합성 DNA 시트로 구성되어 있습니다. 혈류에 주입되면 나노 크기의 DNA 시트는 종양 세포를 찾아 표면에 결합하고 혈액 응고 효소를 도입하여 종양 세포의 생존에 필요한 혈액 공급을 효과적으로 박탈하도록 설계되었습니다.

이 작은 로봇은 암 치료의 과제인 암세포를 근절하는 동시에 주변의 건강한 조직에 대한 손상을 최소화하는 데 도움을 줄 수 있습니다. 그러나 제조의 복잡성이 시장 성장의 걸림돌이 될 수 있습니다. 한편, 연구 활동을 장려하기 위한 자금 지원과 같은 정부의 노력은 나노테크놀러지 약물전달 시장의 성장 기회로 작용할 것으로 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
    • 영향요인
    • 주요 투자 기회
  • Porter's Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
      • 만성질환 증가
      • 나노테크놀러지 진보
    • 성장 억제요인
      • 제조의 복잡성
    • 기회
      • 정부 이니셔티브
  • COVID-19의 시장에 대한 영향 분석

제4장 나노테크놀러지 약물전달 시장 : 제제별

  • 개요
  • 지질 기반 나노의학
  • 폴리머 기반 나노의학
  • 나노결정
  • 기타

제5장 나노테크놀러지 약물전달 시장 : 용도별

  • 개요
  • 종양학 및 혈액학
  • 감염증
  • 정형외과
  • 신경학
  • 비뇨기과
  • 면역학
  • 기타

제6장 나노테크놀러지 약물전달 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 브라질
    • 사우디아라비아
    • 남아프리카공화국
    • 기타 지역

제7장 경쟁 상황

  • 서론
  • 주요 성공 전략
  • 주요 10개사 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝, 2022년

제8장 기업 개요

  • Abbvie Inc
  • Pfizer Ltd
  • AstraZeneca plc
  • Johnson & Johnson
  • Amgen Inc.
  • Merck KGaA
  • Nanobiotix SA
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Bristol-Myers Squibb Company
ksm 23.09.27

According to a new report published by Allied Market Research, titled, "Nanotechnology Drug Delivery Market," The nanotechnology drug delivery market was valued at $87.5 billion in 2022, and is estimated to reach $209.5 billion by 2032, growing at a CAGR of 9.1% from 2023 to 2032. Nanotechnology has revolutionized the field of drug delivery by offering innovative solutions to overcome challenges in targeted therapy, enhanced drug efficacy, and improved patient outcomes. The nanotechnology-based drug delivery market has witnessed significant growth and holds immense potential for the future of medicine. Nanoparticles, nano emulsions, and nanocarriers are some of the key components of nanotechnology used in drug delivery systems. These nanoscale structures possess unique physicochemical properties, such as a high surface area-to-volume ratio and the ability to encapsulate and deliver therapeutic agents to specific target sites in the body.

Nanotechnology Drug Delivery Market - IMG1

The nanotechnology drug delivery market is driven by rise in prevalence of chronic diseases, and advancements in nanotechnology. The rise in prevalence of chronic diseases has emerged as a major driver for the nanotechnology drug delivery market. Chronic diseases, such as cancer, diabetes, cardiovascular diseases, and respiratory disorders, continue to pose significant health challenges globally. According to International Diabetes Federation, in 2021, it was estimated that approximately 537 million people were living with diabetes. Furthermore, according to the same source, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. For instance, researchers from Monash University, RMIT University, The University of Melbourne and the Baker Institute developed a system that responds to glucose, which current insulin does not.

The preclinical study engineered a superior artificial pancreas system to release insulin only when it is genuinely required by the body, resulting in a more dependable regulation of blood glucose levels. This innovative nano sugar platform facilitated prompt and consistent insulin delivery that responded to glucose levels, surpassing other systems in terms of duration and intelligence. The unique capabilities of nanotechnology in enhancing drug delivery precision, targeting, and personalized medicine have positioned it as a promising solution to address the challenges associated with chronic disease management. Thus, the rise in prevalence of chronic diseases has become a key driving force behind the growth of the nanotechnology drug delivery market.

Furthermore, technological advancements in nanomedicines are expected to play a significant role in the growth of the nanotechnology drug delivery market. The limitations of traditional drug delivery systems (DDSs) have led to a significant rise in the popularity of nanocarriers. For instance, scientists at Arizona State University have created an "origami nanorobot" known as such due to its ability to transform into different forms. It comprises a flat synthetic DNA sheet coated with a blood-clotting enzyme. Once injected into the bloodstream, the nanoscale DNA sheet is designed to locate tumor cells, bind to their surface, and introduce the blood-clotting enzyme, effectively depriving the tumor cell of the necessary blood supply for its survival.

This tiny robot addresses a challenging aspect of cancer treatment, which involves eradicating cancer cells while minimizing damage to nearby healthy tissue. However, manufacturing complexities might act as a restraint for the growth of the market. On the other hand, government initiatives such as funding to encourage research activities are expected to serve as growth opportunity in the nanotechnology drug delivery market. The nanotechnology drug delivery market is segmented on the basis of formulation, application, and region. formulation, the market is categorized into lipid-based nanomedicine, polymer-based nanomedicine, nanocrystals, and others.

The others include inorganic nanoparticles, protein-based nanoparticles, and micelles. On the basis of application, the market is categorized into oncology & hematology, infectious diseases, orthopedics, neurology, urology, immunology, and others. The others include gastrointestinal, inflammatory, endocrine, integumentary ophthalmology, and cardiology.

On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). The key players that operate in the global nanotechnology drug delivery market are AbbVie Inc, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Amgen Inc, Merck KGaA, Nanobiotix SA, Novartis AG, Bristol-Myers Squibb Company, and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nanotechnology drug delivery market analysis from 2022 to 2032 to identify the prevailing nanotechnology drug delivery market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the nanotechnology drug delivery market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global nanotechnology drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Formulation

  • Lipid-based nanomedicine
  • Polymer-based nanomedicine
  • Nanocrystals
  • Others

By Application

  • Oncology and Hematology
  • Infectious diseases
  • Orthopedics
  • Neurology
  • Urology
  • Immunology
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Abbvie Inc
    • Amgen Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Merck KGaA
    • Nanobiotix SA
    • Novartis AG
    • Pfizer Ltd
    • Teva Pharmaceutical Industries Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of chronic diseases.
      • 3.4.1.2. Advancement in nanotechnology
    • 3.4.2. Restraints
      • 3.4.2.1. Manufacturing Complexities
    • 3.4.3. Opportunities
      • 3.4.3.1. Government initiatives
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY FORMULATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Lipid-based nanomedicine
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Polymer-based nanomedicine
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Nanocrystals
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oncology and Hematology
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Infectious diseases
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Orthopedics
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Neurology
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Urology
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Immunology
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Others
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country

CHAPTER 6: NANOTECHNOLOGY DRUG DELIVERY MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Formulation
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Formulation
      • 6.2.4.1.3. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Formulation
      • 6.2.4.2.3. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Formulation
      • 6.2.4.3.3. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Formulation
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Formulation
      • 6.3.4.1.3. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Formulation
      • 6.3.4.2.3. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Formulation
      • 6.3.4.3.3. Market size and forecast, by Application
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Formulation
      • 6.3.4.4.3. Market size and forecast, by Application
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Formulation
      • 6.3.4.5.3. Market size and forecast, by Application
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Formulation
      • 6.3.4.6.3. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Formulation
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Formulation
      • 6.4.4.1.3. Market size and forecast, by Application
      • 6.4.4.2. Japan
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Formulation
      • 6.4.4.2.3. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Formulation
      • 6.4.4.3.3. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Formulation
      • 6.4.4.4.3. Market size and forecast, by Application
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Formulation
      • 6.4.4.5.3. Market size and forecast, by Application
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Formulation
      • 6.4.4.6.3. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Formulation
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Formulation
      • 6.5.4.1.3. Market size and forecast, by Application
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Formulation
      • 6.5.4.2.3. Market size and forecast, by Application
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Formulation
      • 6.5.4.3.3. Market size and forecast, by Application
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Formulation
      • 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbvie Inc
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. Pfizer Ltd
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. AstraZeneca plc
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Johnson & Johnson
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Amgen Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
  • 8.6. Merck KGaA
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. Nanobiotix SA
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Novartis AG
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Teva Pharmaceutical Industries Limited
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제